A recent study has found that people with asthma who take semaglutide, a drug commonly used for weight loss and diabetes management, may experience fewer asthma attacks. The research suggests that individuals receiving higher doses of the drug saw a stronger reduction in flare-ups of asthma or chronic obstructive pulmonary disease (COPD). Those with more severe asthma appeared to benefit the most from the treatment. Semaglutide is the active ingredient in Ozempic, a diabetes medication, and Wegovy, a drug used for weight management. It belongs to a class of medications known as GLP-1 receptor agonists, which help regulate blood sugar levels and promote a feeling of fullness by slowing digestion. These drugs have been widely prescribed for metabolic conditions, but this study explores their potential impact on respiratory health. The study, presented at the European Respiratory Society Congress in Barcelona, Spain, analyzed medical records of tens of thousands of people in the UK who began taking GLP-1 receptor agonists. Researchers investigated whether these medications were associated with fewer severe respiratory flare-ups. According to Professor Chloe Bloom, who led the study, semaglutide showed the strongest effect, with people who have asthma experiencing nearly a 40% reduction in asthma attacks. It also led to a 20% decrease in COPD flare-ups. While the findings are encouraging, experts caution that they should not influence treatment decisions without further evidence. Professor Bloom emphasized that people with asthma or COPD should not start taking GLP-1 receptor agonists solely for their lung condition unless advised by a healthcare provider. The results need to be confirmed through clinical trials before they can be applied more broadly. Dr. Alexander Mathioudakis, chairman of the European Respiratory Society’s Group on Airway Pharmacology and Treatment, praised the study for being one of the largest real-world investigations into GLP-1 receptor agonists and respiratory diseases. He noted that the study is also one of the first to compare the effects of different GLP-1 drugs on airway conditions. He highlighted the importance of integrating metabolic health into respiratory care and advocated for including lung-related outcomes in future trials of metabolic medications. Dr. Samantha Walker, director of research and innovation at Asthma + Lung UK, welcomed the findings, stating that they show a significant reduction in asthma and COPD flare-ups among people already taking semaglutide for diabetes or obesity. She emphasized that the benefits were more pronounced in asthma patients compared to other GLP-1 agonists. Dr. Walker also pointed out that the research builds on previous studies funded by Asthma + Lung UK, which aim to improve the understanding of lung health treatments. She called for increased investment in research to enhance the quality of life for people living with lung conditions.